Myriad Genetics Reports Fiscal Fourth-Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Jefferies Remains Sidelined on Myriad Genetics (MYGN) Following 4Q
August 11, 2016 8:37 AM EDTJefferies maintained a Hold rating on Myriad Genetics (NASDAQ: MYGN), and cut the price target to $20.00 (from $34.00), following the company's 4Q earnings report. The company's weaker 4Q16 experience (-7%) and initial FY17 outlook for the HC segment (-7%) suggest pricing and... More
Barclays Downgrades Myriad Genetics (MYGN) to Equalweight
August 10, 2016 7:40 AM EDTBarclays downgraded Myriad Genetics (NASDAQ: MYGN) from Overweight to Equalweight with a price target of $24.00 (from $50.00).
For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.
Shares of Myriad Genetics closed at $29.46 yesterday.
... MoreMizuho Securities Cuts Price Target on Myriad Genetics (MYGN) to $22 Following 4Q and Guidance
August 10, 2016 7:19 AM EDTMizuho Securities maintained a Neutral rating on Myriad Genetics (NASDAQ: MYGN), and cut the price target to $22.00 (from $34.00), following the company's 4Q results and guidance. MYGN guided to 2017 revenues of $740mm-$760mm, versus consensus of $790mm, and EPS of $1.00-$1.10, versus consensus of $1.77.... More
Wells Fargo Downgrades Myriad Genetics (MYGN) to Market Perform
August 10, 2016 7:03 AM EDTWells Fargo downgraded Myriad Genetics (NASDAQ: MYGN) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.
Shares of Myriad Genetics closed at $29.46 yesterday.
... MorePiper Jaffray Downgrades Myriad Genetics (MYGN) to Neutral
August 10, 2016 6:38 AM EDTPiper Jaffray downgraded Myriad Genetics (NASDAQ: MYGN) from Overweight to Neutral with a price target of $22.00 (from $47.00).
Analyst William Quirk commented, "Myriad's 4Q16 revenue declined 1.8% yoy to $186.5M, below our in line estimate of $187.7M. EPS of $0.36 was below our in line $0.37 estimate.... More
Myriad Genetics (MYGN) Misses Q4 EPS by 6c; Issues Weak Q1, FY17 Outlook
August 9, 2016 4:11 PM EDTMyriad Genetics (NASDAQ: MYGN) reported Q4 EPS of $0.32, $0.06 worse than the analyst estimate of $0.38. Revenue for the quarter came in at $186.5 million versus the consensus estimate of $187.92 million.
GUIDANCE:
Myriad Genetics sees Q1 2017 EPS of $0.25-$0.27, versus the consensus of... More
